All
Differentiating Among Oral Ulcers
September 1st 2003San Francisco - A multitude of conditions, from systemic diseases to conditions affecting only the mouth or the alimentary tract, can cause oral ulcers. Recognizing subtle differences in symptoms and knowing which conditions are most common can help dermatologists make accurate diagnosis.
But My Former Physician Employee and I Had a Deal
September 1st 2003Dr. G has a very busy dermatology practice in a large city. When he sought to hire a young physician to join his practice, he wanted to be certain that this physician would never compete with him. The young physician, coming right out of his residency-training program, had no problem with the concept.
Tough Topicals Expand Tx Arsenal
September 1st 2003San Francisco - The topical immunomodulators imiquimod (Aldara), tacrolimus (Protopic), and pimecrolimus (Elidel) are proving to be extremely useful agents for the effective management of a number of skin conditions, Mark Lebwohl, M.D., said at the annual meeting of the American Academy of Dermatology.
SARS Update: Calm For Now, but Storm Might Follow
September 1st 2003With only 10 official SARS patients throughout China since August 1, the word of eradication is becoming hopeful in a country where Severe Acute Respiratory Syndrome seems like a bad dream. But, the reality is that SARS may be an unstoppable nightmare.
Use of TNF Inhibitors: The Changing Treatment Paradigm
August 1st 2003Current therapies for psoriasis can be very effective and are acceptable to many patients. However, a number of drawbacks associated with these treatments may compromise their effectiveness. Patients undergoing ultraviolet B (UVB) phototherapy or psoralen plus ultraviolet A (PUVA) treatments must keep their appointments 3 times a week to maintain the effectiveness of the therapy.
Long-term Safety and Tolerability Experience with TNF Inhibitors
August 1st 2003The class of agents known as TNF inhibitors shares some common safety issues, but the safety profiles of specific agents vary due to differing characteristics and mechanisms. Comparing safety data of these drugs is, of course, complicated by differences in patient populations and experiences.
Higher Dosing 'Difficult to Straddle'
August 1st 2003Chicago - Escalating doses of an antibody to CTLA-4 in conjunction with a peptide vaccine showed the induction of antigen-specific immune responses and potential evidence of autoimmunity in patients with stage III/IV resected melanoma, according to Jeffrey M. Weber, M.D., Ph.D.
Bevacizumab Results Favorable But Not Definitive
August 1st 2003Chicago - A phase II trial of a new recombinant agent in the fight against melanoma has accrued 28 patients so far, yielding interesting data but so far no conclusive results, according to an abstract presented at this year's annual meeting of the American Society of Clinical Oncology.